Mira Toister-Achituv 1, Ziv Porat*2, Doron Kalimi*1, Ohad Tarcic 1, Nir Berger 1, Achim Doerner 3, Arie Zauberman4
* – equal contributors
1 Antibody and Imaging Technologies Group, R&D department, Inter-Lab, a subsidiary of Merck KGaA, Israel
2 Head of Flow Cytometry Unit – Weizmann Institute of Science, Rehovot, Israel
3 Protein Engineering and Antibody Technology group, DDTech department, Merck KGaA, Germany
4 R&D department, Inter-Lab, a subsidiary of Merck KGaA, Israel
Mira Toister-Achituv: Address: Inter-Lab Ltd, South Industrial Area, 18 Ha’Kishon St. 8122004, Yavne, Israel; Phone: +972-8-9382478; Mobile: +972-54-6727203; Fax: +972-8-9301013; E-mail: [email protected]
The authors report that at the time this work was carried out, Merck KgaA was the manufacturer of the Amnis® brand ImageStream® that was used in this article.